AR073486A1 - Heterocyclic compound for diabetes - Google Patents

Heterocyclic compound for diabetes

Info

Publication number
AR073486A1
AR073486A1 ARP090103387A AR073486A1 AR 073486 A1 AR073486 A1 AR 073486A1 AR P090103387 A ARP090103387 A AR P090103387A AR 073486 A1 AR073486 A1 AR 073486A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
c1
alkyl group
group optionally
ring
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Ryoma Hara
Ryosuke Tokunohi
Yoshihiro Banno
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009025511 priority Critical
Priority to PCT/JP2009/054095 priority patent/WO2009110520A1/en
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR073486A1 publication Critical patent/AR073486A1/en

Links

Abstract

Reivindicacion 1 Un compuesto caracterizado por la siguiente formula(1) en donde el anillo AA es un anillo benceno opcionalmente sustituido o un heterociclo aromático de 5 o 6 miembros opcionalmente sustituido; A compound claim 1 characterized by the following formula (1) wherein ring AA is a benzene ring optionally substituted or an aromatic 5- or 6 members optionally substituted; el anillo AB es un heterociclo aromático de 5 miembros opcionalmente sustituido; ring AB is an aromatic 5-membered heterocycle optionally substituted; el anillo AC es un anillo benceno opcionalmente sustituido o un heterociclo aromático de 5 o 6 miembros opcionalmente sustituido; AC ring is a benzene ring optionally substituted heterocycle or an aromatic 5 or 6 membered optionally substituted; RA3 un grupo alquilo C1-6 opcionalmente sustituido, es un grupo cicloalquilo C3-10 opcionalmente sustituido, es un grupo arilo C6-14 opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido; RA3 an alkyl group optionally substituted C1-6, a C3-10 cycloalkyl group optionally substituted, a C6-14 aryl group optionally substituted or a heterocyclic group optionally substituted; RA4 es un átomo de hidrogeno o un grupo alquilo C1-6; RA4 is a hydrogen atom or C1-6 alkyl group; RA5 es -(CH2)3-COORA11 o -NRA6-CRA7RA8-CRA9RA10-COORA11; RA5 is - (CH2) 3-COORA11 or -NRA6-CRA7RA8-CRA9RA10-COORA11; RA6, RA7, RA8, RA9 y RA11 son cada uno, de modo independiente, un átono de hidrogeno o un grupo alquilo C1-6; RA6, RA7, RA8, RA9 and RA11 are each independently a hydrogen atonic or C1-6 alkyl group; y RA10 es un átomo de hidrogeno, un grupo alquilo C1-6 o un grupo hidroxi, o una de sus sales. and RA10 is a hydrogen atom, C1-6 alkyl group or a hydroxy group, or a salt thereof. Reivindicacion 11: Un compuesto caracterizado por la siguiente formula (2) donde el anillo A es un anillo benceno opcionalmente sustituido o un heterociclo aromático do 5 o 6 miembros opcionalmente sustituido; Claim 11: A compound characterized by the following formula (2) wherein ring A is a benzene ring optionally substituted or an aromatic heterocycle optionally do 5- or 6 members substituted; el anillo B es pirazol; ring B is pyrazole; R1 y R2 son cada uno, de modo independiente, un grupo hidrocarbonado opcionalmente sustituido, un grupo heterocíclico opcionalmente sustituido, un grupo hidroxi opcionalmente sustituido o acilo; R1 and R2 are each, independently, a hydrocarbon group optionally substituted, a heterocyclic group optionally substituted, a hydroxy group optionally substituted or acyl; R3 es un grupo alquilo C1-6 opcionalmente sustituido, es un grupo cicloalquilo C3-10 opcionalmente sustituido, es un grupo arilo C6-14 opcionalmente sustituido o un grupo heterocíclico opcionalmente sustituido; R3 is an alkyl group optionally substituted C1-6, a C3-10 cycloalkyl group optionally substituted, a C6-14 aryl group optionally substituted or a heterocyclic group optionally substituted; R4 es un átomo de hidrogeno o un grupo alquilo C1-6; R4 is a hydrogen atom or C1-6 alkyl group; R5 es -(CH2)3-COOR11 o -NR6-CR7R8-CR9R10-COOR11; R5 is - (CH2) 3-COOR11 or NR6-CR7R8-CR9R10-COOR11; R6, R7, R8, R9 y R11 son cada uno, de modo independiente, un átomo de hidrogeno o un grupo alquilo C1-6; R6, R7, R8, R9 and R11 are each, independently, a hydrogen atom or C1-6 alkyl group; y R10 es un átomo de hidrogeno, un grupo alquilo C1-6 o un grupo hidroxi, excluyendo N-[4-[[(1-fenil-5-propil-1H-pirazol-4-il)metil]amino]benzoil]-beta-alanina o una de sus sales. and R10 is a hydrogen atom, alkyl group or C1-6 a hydroxy group, excluding N- [4 - [[(1-phenyl-5-propyl-1H-pyrazol-4-yl) methyl] amino] benzoyl] -beta-alanine or a salt thereof.
ARP090103387 2008-03-05 2009-09-02 Heterocyclic compound for diabetes AR073486A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009025511 2009-02-06
PCT/JP2009/054095 WO2009110520A1 (en) 2008-03-05 2009-03-04 Heterocyclic compound

Publications (1)

Publication Number Publication Date
AR073486A1 true AR073486A1 (en) 2010-11-10

Family

ID=42561095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103387 AR073486A1 (en) 2008-03-05 2009-09-02 Heterocyclic compound for diabetes

Country Status (5)

Country Link
AR (1) AR073486A1 (en)
CL (1) CL2009001796A1 (en)
PE (1) PE20100443A1 (en)
TW (1) TWI475018B (en)
UY (1) UY32088A (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
WO2003048109A1 (en) * 2001-12-03 2003-06-12 Novo Nordisk A/S Novel glucagon antagonists
DK1618092T3 (en) * 2003-05-01 2011-01-31 Squibb Bristol Myers Co Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
AU2004238240A1 (en) * 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
US7696248B2 (en) * 2005-11-17 2010-04-13 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses

Also Published As

Publication number Publication date
PE20100443A1 (en) 2010-06-25
TWI475018B (en) 2015-03-01
UY32088A (en) 2010-08-31
CL2009001796A1 (en) 2011-09-16
TW201029996A (en) 2010-08-16

Similar Documents

Publication Publication Date Title
Sadowsky et al. Chimeric (α/β+ α)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition
Horne et al. Sequence‐Based Design of α/β‐Peptide Foldamers That Mimic BH3 Domains
Helal et al. Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer’s disease
Galdeano et al. Structure-guided design and optimization of small molecules targeting the protein–protein interaction between the von Hippel–Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities
Stokes et al. Rh2 (II)-Catalyzed nitro-group migration reactions: selective synthesis of 3-nitroindoles from β-nitro styryl azides
AR086654A1 (en) Compositions containing dye clothing care
RU2430913C2 (en) Cycloalkylamines as monoamine reuptake inhibitors
CO5721002A2 (en) Derivatives of 3- (4-benzyloxyphenyl) propanoic acid
CY1113631T1 (en) Derivatives speiroeterokyklikis pyrrolidine dionis USEFUL AS HERBICIDES
PE20040960A1 (en) Acylated piperazine derivatives as agonists of the melanocortin receptor-4
AR086539A1 (en) COMPOUNDS FOR REDUCING PRODUCTION amyloid-b
RU2015105249A (en) Mtor kinase inhibitors for oncological indications and diseases related to mtor / pi3k / akt by metabolism
MX2010014224A (en) A process for the preparation of the apoptosis promoter abt-263.
CR20110194A (en) Pyrazole compounds for controlling invertebrate pests
CO6251266A2 (en) Pyridyl piperidine antagonists of the orexin
AR067759A1 (en) Pyrazole compounds useful as modulators of raf enzyme associated with abnormal cell growth
DOP2013000139A (en) Amides aminoindanes with high fungicidal activity and phytosanitary compositions
CA2662773A1 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CO5550451A2 (en) Derivatives of 3- (sulfonamidoetil) -indole cos mimetic for use as glucocorticoid in the treatment of inflammatory, allergic and proliferative diseases
TW201129674A (en) Organic light-emitting medium
AR035548A1 (en) organic compounds
UY30292A1 (en) Derivatives of 4- (2-amino-1-hydroxyethyl) phenol as the receptor agonists b (beta) 2 adrenergic
BR0212760A (en) Chemical compounds
PE20140207A1 (en) Compositions and methods for modulating FXR
CY1117776T1 (en) Enantiomer COMPOUNDS spiro-oxindole and USES AS THERAPEUTIC AGENTS